Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | VDR | P11473 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10950116 | 0.94 | STAT3 (0.36) | STAT3ALDH1A1CA12CA1CA9 | |
| SCHEMBL690833 | 0.92 | STAT3 (0.40) | STAT3ALDH1A1CA12CA1CA9 | |
| SCHEMBL10015860 | 0.87 | ALDH1A1 (0.37) | STAT3ALDH1A1CA12CA1CA9 | |
| SCHEMBL24194808 | 0.87 | STAT3 (0.39) | STAT3ALDH1A1CA12CA1CA9 | |
| SCHEMBL16572522 | 0.87 | STAT3 (0.36) | STAT3ALDH1A1CA12CA1CA9 | |
| SCHEMBL8598041 | 0.85 | CYP3A4 (0.46) | STAT3ALDH1A1CA12CA1CA9 | |
| SCHEMBL16835 | 0.83 | KMT2A (0.44) | STAT3ALDH1A1CA12CA1CA9 | |
| SCHEMBL18218 | 0.83 | KMT2A (0.47) | STAT3ALDH1A1CA12CA1CA9 | |
| SCHEMBL2578056 | 0.83 | PDE9A (0.36) | STAT3ALDH1A1CA12CA1CA9 | |
| SCHEMBL15970201 | 0.83 | GLA (0.39) | STAT3ALDH1A1CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109265359-B | Side chain type water-soluble polyquaternary ammonium salt and preparation method thereof | 大连百傲化学股份有限公司 | 2021-09-03 | — | — | CN | claimed |
| JP-11228558-A | — | — | None | — | — | JP | disclosed |
| US-12545666-B2 | Itraconazole analogs and use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-02-10 | — | — | US | disclosed |
| US-20240140959-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS AG (CH) | 2024-05-02 | — | — | US | disclosed |
| US-11820778-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | NOVARTIS AG (CH) | 2023-11-21 | — | — | US | disclosed |
| US-20220411435-A1 | 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-12-29 | — | — | US | disclosed |
| US-20220363672-A1 | ITRACONAZOLE ANALOGS AND USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2022-11-17 | — | — | US | disclosed |
| US-11485742-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | NOVARTIS AG (CH) | 2022-11-01 | — | — | US | disclosed |
| EP-4041737-A1 | 5-OXA-2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | Novartis AG (CH) | 2022-08-17 | — | — | EP | disclosed |
| US-11111225-B2 | Calixarene compound and curable composition | DIC CORPORATION (JP) | 2021-09-07 | — | — | US | disclosed |
| US-7407691-B2 | Photopolymerizable oxetane derivative and liquid-crystal composition containing it | CHISSO CORPORATION (JP) | 2008-08-05 | — | — | US | disclosed |
| US-7393569-B2 | Hexafluoroisopropylidenebis- and sulfonylbis-(phenoxycarbonylphenoxyalkyl acrylates); hexafluoroisopropylidenebis- and sulfonylbis-(phenoxycarbonylphenoxyalkyloxetanes; stabilizes polymerizable liquid crystal compositions for a long time and controls the alignment of liquid crystal molecules | CHISSO CORPORATION (JP) | 2008-07-01 | — | — | US | disclosed |
| US-7319132-B2 | Polymer compounds containing oxetane and maleimide functionality | NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319132-B2 | Polymer compounds containing oxetane and maleimide functionality | NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-20070122565-A1 | 1-15% 1,1'-Binaphthyl-2,2'-diol diesterified with 3-alkyl-3-oxetanylmethoxyaryl-carboxylic acid, -propionic acid or -acrylic acid; 5-45% arylenediol diesterified with p-(3-alkyl-3-oxetanylmethoxyalkoxy)benzoic acid; and 45-80% p-(epoxyalkoxy)phenyl p-(epoxyalkoxy)benzoate; optical anisotropy | JNC PETROCHEMICAL CORPORATION (JP) | 2007-05-31 | — | — | US | disclosed |
| US-20060278851-A1 | Polymerizable liquid crystal composition and polymer thereof | CHISSO CORPORATION AND CHISSO PETROCHEMICAL CORPORATION | 2006-12-14 | — | — | US | disclosed |
| US-20060252911-A1 | adamantyl diglycidyl ether or 1-adamantanol epichlorohydrin adduct curable to polyepoxides; encapsulant for light-emitting diode; superior optical properties, heat resistance, photostability, and shrinkage inhibition | TOKYUYAMA CORPORATION (JP) | 2006-11-09 | — | — | US | disclosed |
| EP-1637526-A1 | CURABLE POLYCYCLIC COMPOUNDS AND PROCESS FOR THE PRODUCTION THEREOF | TOKUYAMA CORPORATION (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-20050224757-A1 | Photopolymerizable oxetane derivative and liquid-crystal composition containing it | JNC PETROCHEMICAL CORPORATION (JP) | 2005-10-13 | — | — | US | disclosed |
| JP-H11228558-A | CALIXARENE DERIVATIVE CONTAINING OXETANE GROUP AND PRODUCTION THEREOF | UBE IND LTD | 1999-08-24 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060278851-A1 | Polymerizable liquid crystal composition and polymer thereof | NCAPD2, LANCL2, TAF1 | STAT3 4400/4885ALDH1A1 2478/4885CA12 1117/4885 |
| US-11485742-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | CHRM2, CHRM1, CHRM3 | STAT3 860/4885ALDH1A1 1359/4885CA12 3410/4885 |
| US-20240140959-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | STAT3 860/4885ALDH1A1 1359/4885CA12 3410/4885 |
| US-11111225-B2 | Calixarene compound and curable composition | CALU, CALCRL, CAPN1 | STAT3 4330/4885ALDH1A1 1469/4885CA12 719/4885 |
| US-20220363672-A1 | ITRACONAZOLE ANALOGS AND USE THEREOF | SHH, GLI1, KDR | STAT3 275/4885ALDH1A1 1448/4885CA12 2304/4885 |
| US-20060252911-A1 | adamantyl diglycidyl ether or 1-adamantanol epichlorohydrin adduct curable to polyepoxides; encapsulant for light-emitting diode; superior optical properties, heat resistance, photostability, and shrinkage inhibition | PFN1, FSCN1, PFDN1 | STAT3 4730/4885ALDH1A1 50/4885CA12 3793/4885 |
| US-12545666-B2 | Itraconazole analogs and use thereof | SHH, SMO, GLI1 | STAT3 38/4885ALDH1A1 2379/4885CA12 132/4885 |
| US-20220411435-A1 | 2-AZASPIRO[3,4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | STAT3 908/4885ALDH1A1 1367/4885CA12 3381/4885 |
| US-20050224757-A1 | Photopolymerizable oxetane derivative and liquid-crystal composition containing it | TAC3, CPNE4, CNPY3 | STAT3 3412/4885ALDH1A1 2259/4885CA12 933/4885 |
| US-11820778-B2 | 2-azaspiro[3.4]octane derivatives as M4 agonists | CHRM2, CHRM1, CHRM3 | STAT3 860/4885ALDH1A1 1359/4885CA12 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.